8-K: NeueHealth Reports Strong 2023 Results, Focuses on Value-Driven Care Model

NeueHealth reported a 55% year-over-year revenue increase to $1.2 billion in 2023, driven by its care delivery and provider enablement business, while serving 461,000 consumers.

Summary

• NeueHealth announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company achieved $1.2 billion in revenue for the full year 2023, a 55% increase compared to the previous year.
• NeueHealth served 461,000 consumers in 2023, a 294% increase on a comparable basis.
• The company's full year net loss from continuing operations was $(627.7) million, which includes $(515.8) million related to non-cash items.
• Adjusted EBITDA for the full year was $(8.5) million.
• For 2024, NeueHealth expects enterprise revenue of approximately $1 billion, with NeueCare revenue between $310 million and $320 million, and NeueSolutions revenue between $690 million and $700 million.
• The company anticipates an Enterprise Adjusted EBITDA between $15 million and $25 million in 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with strong revenue growth but significant losses. The forward guidance is positive, but the risks are substantial. The sentiment is neutral to slightly negative.

Positives

• The company achieved a significant 55% year-over-year revenue growth, reaching $1.2 billion in 2023.
• Consumer base increased by 294% on a comparable basis, reaching 461,000 consumers.
• The company is projecting positive Adjusted EBITDA for 2024, between $15 million and $25 million.
• The company has successfully refocused its business on care delivery and provider enablement after exiting its California Medicare Advantage business.

Negatives

• The company reported a substantial net loss from continuing operations of $(627.7) million for 2023.
• The company's Adjusted EBITDA was negative at $(8.5) million for the full year 2023.
• The company's operating expenses were significantly higher than revenue, contributing to the net loss.

Risks

• The company's ability to continue as a going concern is a risk.
• There are risks associated with the company's ability to comply with the terms of its credit facility.
• The company's ability to receive the remaining proceeds from the sale of its Medicare Advantage business in California in a timely manner is a risk.
• The company's ability to obtain necessary short or long term debt or equity financing is a risk.
• There are risks associated with the wind down of the company's IFP and MA businesses outside of California.
• Potential disruptions to the business due to corporate restructuring and headcount reduction are a risk.
• The company's ability to accurately estimate and manage costs related to changes in business offerings is a risk.
• There is a risk of a delay or inability to withdraw regulated capital from subsidiaries.
• A lack of acceptance or slow adoption of the company's business model is a risk.
• The company's ability to retain existing consumers and expand enrollment is a risk.
• The company's ability to accurately assess, code, and report risk adjustment factor scores is a risk.
• The company's ability to contract with care providers and arrange for quality care is a risk.
• The company's ability to accurately estimate medical expenses and manage costs is a risk.
• The company's reliance on third-party providers is a risk.
• The impact of modifications or changes to the U.S. health insurance markets is a risk.
• The company's ability to manage growth is a risk.
• The company's ability to operate and update its technology platform is a risk.
• The company's ability to retain key executives is a risk.
• The company's ability to successfully pursue acquisitions and integrate acquired businesses is a risk.
• The occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest are risks.
• The company's ability to prevent and contain data security incidents is a risk.
• The company's ability to comply with requirements to maintain effective internal controls is a risk.
• The company's ability to adapt to the new risks associated with its ACO Reach businesses is a risk.

Future Outlook

NeueHealth expects approximately $1 billion in enterprise revenue for 2024, with NeueCare revenue between $310 million and $320 million, and NeueSolutions revenue between $690 million and $700 million. The company anticipates an Enterprise Adjusted EBITDA between $15 million and $25 million in 2024.

Management Comments

• Mike Mikan, President and CEO of NeueHealth, stated that the company achieved significant milestones in the past year, completing the sale of their California Medicare Advantage business.
• Mike Mikan also stated that the company is fully focused on care delivery and provider enablement, where they have proven to have the greatest impact.
• Management expressed confidence in the value-driven, consumer-centric care model and its ability to align the interests of providers, payors, and consumers.

Industry Context

This announcement reflects a broader trend in the healthcare industry towards value-based care models and a focus on provider enablement. The company's shift away from the Medicare Advantage business in California and towards its core care delivery and provider enablement business aligns with this trend.

Comparison to Industry Standards

• The 55% year-over-year revenue growth is significant, but the large net loss indicates that the company is still in a growth phase and is not yet profitable.
• The projected Adjusted EBITDA of $15 million to $25 million for 2024 is a positive sign, but it is important to compare this to other companies in the healthcare sector with similar business models.
• Companies like Oak Street Health and Agilon Health are also focused on value-based care, and their financial performance can be used as a benchmark for NeueHealth.
• The company's consumer growth of 294% is impressive, but it is important to assess the cost of acquiring these consumers and their long-term value.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss, but encouraged by the revenue growth and positive Adjusted EBITDA guidance for 2024.
• Employees may be affected by potential corporate restructuring and headcount reduction.
• Customers should benefit from the company's focus on value-driven, consumer-centric care.
• Providers should benefit from the company's provider enablement services.
• Creditors may be concerned about the company's ability to comply with its credit facility and obtain necessary financing.

Next Steps

• NeueHealth will discuss the company's results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today.
• The company will continue to focus on its care delivery and provider enablement business.
• The company will work towards achieving its 2024 financial guidance.

Key Dates

Keywords

Healthcare, Value-Based Care, Provider Enablement, Adjusted EBITDA, Revenue, Financial Results, NeueCare, NeueSolutions, ACO REACH, Medicare Advantage